Congress Set To Expand FDA Priority Review Vouchers; Some Raise Concerns Over Program

CQ HealthBeat: Popular Priority Drug Reviews Face Scrutiny
“…Since the priority review voucher program was established in 2007, only nine have been awarded, mostly for drugs treating rare pediatric diseases and some for tropical diseases like malaria and tuberculosis. But five of those were awarded in 2015 alone. With Congress poised to expand the program, the pace could increase. That raised concerns within the Food and Drug Administration about whether it has the resources to handle the faster approval timelines. Others note that companies can win vouchers for drugs that were already approved years earlier in other countries, which limits the incentives to pursue innovative treatments…” (Siddons, 3/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.